Methods of improving neurodegenerative disorders by targeted delivery of therapeutic agents
A method of improving a neurodegenerative or cognitive disorder in a human patient suffering therefrom is provided by determining a target site of the human patient's brain that is affected by the neurodegenerative disorder or cognitive disorder and providing a therapy to the human patient. The therapy includes applying a low intensity focused ultrasound (LiFUS) sonication via an ultrasound delivery device to the target site based on an imaging parameter, a microbubble cavitation; an optical parameter, a bodily fluid parameter, or a physiological or anatomical parameter of the human patient's brain. A therapeutic agent is introduced to the target site before, after or during application of the LiFUS sonication.
1 . A method of improving a neurodegenerative disorder in a human patient suffering therefrom comprising:
determining a target site of the human patient's brain that is affected by the neurodegenerative disorder; and
providing a therapy to the human patient comprising:
applying a focused ultrasound (FUS) sonication via an ultrasound delivery device to the target site based on at least one feedback parameter comprising at least one or more of an imaging parameter; an acoustic microbubble vibration analysis; an optical parameter; a bodily fluid parameter; or a physiological or anatomical parameter; and
introducing a therapeutic agent to the target site before, during, or after application of the FUS sonication.
2 . The method of claim 1 , wherein the determining step comprises determining one or more regions of the human patient's brain having a beta amyloid protein, a tau protein, Alpha synuclein, lysosomal enzymes, markers of amyloid and tau pathology, neurofilament light chain and other biomarkers detected in blood, CSF, brain, and other tissues and body fluids, and/or another biomarker of the neurodegenerative disorder.
3 . The method of claim 1 , wherein the imaging parameter comprises a PET scan, MRI scans such as: 1—blood sensitive sequences based on gradient recalled echo (GRE) such as T2*-weighted imaging (GRE T2*) scan or a susceptibility weighted imaging (SWI) scan, 2—magnetization T1 preparation sequence scan, 3—T2 weighted fluid attenuation inversion recovery (FLAIR) scan, 4—T1 contrast scan, 5—an arterial spin labeling (ASL) scan, a 6—dynamic contrast-enhanced (DCE) MR perfusion scan, 7—connectivity diffusion tensor imaging (DTI) scan, 8—functional MRI; 9—Acoustic radiation force imaging (ARFI); 10—spectroscopy; 11—membrane disruption scans; 12—acoustic radiation force imaging or combinations thereof of the human patient's brain.
4 . The method of claim 3 , further comprising:
determining changes in a concentration of a beta-amyloid protein, a tau protein and/or another biomarker of the neurodegenerative based on the PET scan or an optical coherence tomography scan; and
delivering or adjusting the therapy based on the changes in concentration.
5 . The method of claim 4 , wherein delivering or adjusting the therapy comprises at least one or more of providing therapy, not providing therapy, changing a frequency of providing the therapy, adjusting the dose of the LiFUS sonication application, adjusting a timing of applying the LiFUS sonication, changing a frequency of application of the LiFUS sonication, terminating application of the LiFUS sonication, continuing application of the LiFUS sonication, changing one or more of the ultrasound delivery device parameters, changing a location of the therapy from the target site to another site of the human patient's brain, changing a dose of an administration of microbubbles, changing a timing of an administration of microbubbles, conducting acoustic microbubble vibration analysis, changing a dose of the therapeutic agent, changing a time of introduction of the therapeutic agent, or changing a frequency of the introduction of the therapeutic agent.
6 . The method of claim 4 , further comprising:
determining if there is an increase or decrease in a GRE T2* signal as indicated by the GRE T2* scan compared to a threshold value or a GRE T2* signal as indicated by a GRE T2* scan taken prior to therapy; and
delivering or adjusting the therapy based on the increase or the decrease in the GRE T2* signal.
7 . The method of claim 6 , wherein delivering or adjusting the therapy comprises at least one or more of providing therapy, not providing therapy, changing a frequency of providing the therapy, adjusting the dose of the LiFUS sonication application, adjusting a timing of applying the LIFUS sonication, changing a frequency of application of the LiFUS sonication, terminating application of the LiFUS sonication, continuing application of the LiFUS sonication, changing one or more of the ultrasound delivery device parameters, changing a location of the therapy from the target site to another site of the human patient's brain, changing a dose of an administration of microbubbles, changing a timing of an administration of microbubbles, conducting acoustic microbubble vibration analysis, changing a dose of the therapeutic agent, changing a time of introduction of the therapeutic agent, or changing a frequency of the introduction of the therapeutic agent.
8 . The method of claim 4 , further comprising:
determining if there is an increase or decrease in a T1 contrast signal as indicated by the T1 contrast scan compared to a threshold value or a T1 contrast signal as indicated by a T1 contrast scan taken prior to therapy; and
delivering or adjusting the therapy based on the increase or the decrease in the T1 contrast signal.
9 . The method of claim 8 , wherein delivering or adjusting the therapy comprises at least one or more of providing therapy, not providing therapy, changing a frequency of providing the therapy, adjusting the dose of the LiFUS sonication application, adjusting a timing of applying the LIFUS sonication, changing a frequency of application of the LiFUS sonication, terminating application of the LiFUS sonication, continuing application of the LiFUS sonication, changing one or more of the ultrasound delivery device parameters, changing a location of the therapy from the target site to another site of the human patient's brain, changing a dose of an administration of microbubbles, changing a timing of an administration of microbubbles, conducting acoustic microbubble vibration analysis, changing a dose of the therapeutic agent, changing a time of introduction of the therapeutic agent, or changing a frequency of the introduction of the therapeutic agent.
10 . The method of claim 4 , further comprising:
determining if there is an increase or decrease in a T2 weighted FLAIR signal as indicated by the T2 weighted FLAIR scan compared to a threshold value or a T2 weighted FLAIR signal as indicated by a T2 weighted FLAIR scan taken prior to therapy; and
delivering or adjusting the therapy based on the increase or the decrease in the T2 weighted FLAIR signal.
11 . The method of claim 10 , wherein delivering or adjusting the therapy comprises at least one or more of providing therapy, not providing therapy, changing a frequency of providing the therapy, adjusting the dose of the LiFUS sonication application, adjusting a timing of applying the LIFUS sonication, changing a frequency of application of the LiFUS sonication, terminating application of the LiFUS sonication, continuing application of the LiFUS sonication, changing one or more of the ultrasound delivery device parameters, changing a location of the therapy from the target site to another site of the human patient's brain, changing a dose of an administration of microbubbles, changing a timing of an administration of microbubbles, conducting acoustic microbubble vibration analysis, changing a dose of the therapeutic agent, changing a time of introduction of the therapeutic agent, or changing a frequency of the introduction of the therapeutic agent.
12 . The method of claim 4 , further comprising:
determining if there is an increase or decrease in a SWI signal as indicated by the SWI scan compared to a threshold value or a SWI signal as indicated by a SWI scan taken prior to therapy; and
delivering or adjusting the therapy based on the increase or the decrease in the SWI signal.
13 . The method of claim 12 , wherein delivering or adjusting the therapy comprises at least one or more of providing therapy, not providing therapy, changing a frequency of providing the therapy, adjusting the dose of the LiFUS sonication application, adjusting a timing of applying the LIFUS sonication, changing a frequency of application of the LiFUS sonication, terminating application of the LiFUS sonication, continuing application of the LiFUS sonication, changing one or more of the ultrasound delivery device parameters, changing a location of the therapy from the target site to another site of the human patient's brain, changing a dose of an administration of microbubbles, changing a timing of an administration of microbubbles, conducting acoustic microbubble vibration analysis, changing a dose of the therapeutic agent, changing a time of introduction of the therapeutic agent, or changing a frequency of the introduction of the therapeutic agent.
14 . The method of claim 1 , wherein the at least on feedback parameter is acoustic microbubble vibration analysis.
15 . The method of claim 14 , further comprising:
analyzing the acoustic microbubble vibration analysis; and
delivering or adjusting the therapy based on the analysis.
16 . The method of claim 15 , wherein delivering or adjusting the therapy comprises at least one or more of providing therapy, not providing therapy, changing a frequency of providing the therapy, adjusting the dose of the LiFUS sonication application, adjusting a timing of applying the LIFUS sonication, changing a frequency of application of the LiFUS sonication, terminating application of the LiFUS sonication, continuing application of the LiFUS sonication, changing one or more of the ultrasound delivery device parameters, changing a location of the therapy from the target site to another site of the human patient's brain, changing a dose of an administration of microbubbles, changing a timing of an administration of microbubbles, changing a dose of the therapeutic agent, changing a time of introduction of the therapeutic agent, or changing a frequency of the introduction of the therapeutic agent.
17 . The method of claim 1 , wherein the bodily fluid parameter is urine, blood, cerebral spinal fluid (CSF), or other bodily fluid or tissue.
18 . The method of claim 17 , further comprising:
determining changes in a concentration of a beta-amyloid protein, a tau protein and/or another biomarker of the neurodegenerative disorder in the urine, blood, CSF, or other bodily fluid and/or tissue; or identifying a presence of a biomarker of the neurodegenerative disorder; or combinations thereof; and
delivering or adjusting the therapy based on the changes in the concentration or the identification of the presence of the biomarker.
19 . The method of claim 18 , wherein delivering or adjusting the therapy comprises at least one or more of providing therapy, not providing therapy, changing a frequency of providing the therapy, adjusting the dose of the LiFUS sonication application, adjusting a timing of applying the LIFUS sonication, changing a frequency of application of the LiFUS sonication, terminating application of the LiFUS sonication, continuing application of the LiFUS sonication, changing one or more of the ultrasound delivery device parameters, changing a location of the therapy from the target site to another site of the human patient's brain, changing a dose of an administration of microbubbles, changing a timing of an administration of microbubbles, conducting acoustic microbubble vibration analysis, changing a dose of the therapeutic agent, changing a time of introduction of the therapeutic agent, or changing a frequency of the introduction of the therapeutic agent.
20 . The method of claim 1 , further comprising:
applying a neuromodulation signal to a brain region during or after introducing the therapeutic agent and/or applying a LiFUS sonication.